0.97
+0.001(+0.10%)
Currency In USD
| Previous Close | 0.97 |
| Open | 0.96 |
| Day High | 1 |
| Day Low | 0.96 |
| 52-Week High | 2.35 |
| 52-Week Low | 0.82 |
| Volume | 161,701 |
| Average Volume | 182,331 |
| Market Cap | 16.5M |
| PE | -1.23 |
| EPS | -0.79 |
| Moving Average 50 Days | 0.97 |
| Moving Average 200 Days | 1.01 |
| Change | 0 |
If you invested $1000 in Microbot Medical Inc. (MBOT) 10 years ago, it would be worth $0.65 as of December 21, 2024 at a share price of $0.975. Whereas If you bought $1000 worth of Microbot Medical Inc. (MBOT) shares 5 years ago, it would be worth $96.39 as of December 21, 2024 at a share price of $0.975.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Microbot Medical® CEO Harel Gadot to Discuss Endovascular Robotics on Benzinga All Access
GlobeNewswire Inc.
Dec 10, 2024 3:18 PM GMT
Livestream Interview Can be Viewed Today at 10:50am ET at Benzinga All Access Live BRAINTREE, Mass., Dec. 10, 2024 (GLOBE NEWSWIRE) -- Microbot Medical® Inc. (Nasdaq: MBOT), developer of the innovative single use LIBERTY® Endovascular Robotic Syste
Microbot Medical® Announces FDA Submission for the Commercialization of the LIBERTY® Endovascular Robotic System
GlobeNewswire Inc.
Dec 10, 2024 1:00 PM GMT
FDA 510(k) Submission Follows the Successful Completion of the Pivotal Human Clinical Trial FDA 510(k) Clearance Anticipated During the Second Quarter of 2025 Company Preparing to Commence Commercialization Following FDA 510(k) Clearance BRAINTREE, M
Microbot Medical Announces the Successful Completion of its Pivotal Human Clinical Trial; Accelerates Go-to-Market Strategy to Prepare for Commercial Launch of LIBERTY® during 2Q 2025
GlobeNewswire Inc.
Oct 15, 2024 12:38 PM GMT
U.S. Food and Drug Administration (FDA) Submission Expected by end of 2024 Clinical Data to be Presented at Medical Conference in Early 2025 BRAINTREE, Mass., Oct. 15, 2024 (GLOBE NEWSWIRE) -- Microbot Medical Inc. (Nasdaq: MBOT), developer of the